ストックスクリーナーアプリを入手
75.73
1.57%
-1.14
前日終値:
$76.87
開ける：
$76.65
24時間の取引高:
144.98K
Relative Volume:
0.11
時価総額：
$8.91B
収益：
$12.50B
当期純損益:
$314.00M
株価収益率:
31.04
EPS:
2.44
ネットキャッシュフロー:
$421.00M
1週間 パフォーマンス:
-4.16%
1か月 パフォーマンス:
-0.62%
6か月 パフォーマンス:
+7.38%
1年 パフォーマンス:
-0.58%
1日の値動き範囲:
$75.30
$76.88
1週間の範囲:
$75.30
$79.44
52週間の値動き範囲:
$60.56
$82.49
Henry Schein Inc Stock (HSIC) Company Profile
HSIC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
75.65 | 9.05B | 12.50B | 314.00M | 421.00M | 2.44 |
|
MCK
Mckesson Corporation
|
823.71 | 102.96B | 387.09B | 4.23B | 6.01B | 32.12 |
|
COR
Cencora Inc
|
349.09 | 69.28B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
CAH
Cardinal Health Inc
|
210.17 | 50.85B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
AHG
Akso Health Group Adr
|
1.40 | 785.36M | 2.22M | -5.63M | -1.68M | -0.24 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-08-26 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2025-07-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-02-14 | 開始されました | Wells Fargo | Equal Weight |
| 2025-01-06 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-12-04 | 開始されました | Mizuho | Neutral |
| 2024-07-22 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-11-10 | アップグレード | Stifel | Hold → Buy |
| 2022-08-08 | アップグレード | UBS | Sell → Neutral |
| 2022-07-21 | ダウングレード | Goldman | Buy → Neutral |
| 2022-06-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-13 | 再開されました | Credit Suisse | Outperform |
| 2022-01-31 | 開始されました | Morgan Stanley | Underweight |
| 2022-01-07 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-10-01 | 再開されました | Credit Suisse | Neutral |
| 2021-02-08 | 再開されました | Piper Sandler | Overweight |
| 2021-01-04 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2020-11-03 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2020-04-07 | アップグレード | Goldman | Neutral → Buy |
| 2020-04-02 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-01-09 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2020-01-02 | アップグレード | Evercore ISI | Underperform → In-line |
| 2019-08-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2019-05-30 | 開始されました | Wolfe Research | Underperform |
| 2019-05-15 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-04-18 | 開始されました | Guggenheim | Buy |
| 2019-01-17 | 開始されました | UBS | Sell |
| 2019-01-03 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2019-01-02 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2018-11-08 | 繰り返されました | Barrington Research | Outperform |
| 2018-10-25 | ダウングレード | Edward Jones | Hold → Sell |
| 2018-10-19 | 再開されました | Goldman | Neutral |
| 2018-10-04 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-08-07 | 繰り返されました | Stifel | Hold |
| 2018-04-24 | ダウングレード | Goldman | Buy → Neutral |
| 2018-04-04 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
すべてを表示
Henry Schein Inc (HSIC) 最新ニュース
Sleeping Bruxism Treatment Market Size to Reach USD 1,132.09 Million by 2033, Driven by Rising Awareness of Sleep Disorders and Oral Health Complications – SNS Insider - GlobeNewswire Inc.
Briefly: NCPA, Henry Schein Announce New Executive Leaders - HME Business
Analyst Downgrade: Will Henry Schein Inc. benefit from green energy policiesEarnings Beat & Expert Approved Trade Ideas - baoquankhu1.vn
Henry Schein Schedules Q4 2025 Earnings Call - Dentistry Today
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail
Henry Schein to Webcast Fourth Quarter 2025 Conference Call on Tuesday, February 24, 2026, at 8:00 A.M. ET - BioSpace
How Investors Are Reacting To Henry Schein (HSIC) New CEO Pick And Exclusive CitoCBC Deal - simplywall.st
Henry Schein Shares Consolidate as Technical and Fundamental Catalysts Align - AD HOC NEWS
Henry Schein Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
Dilation Capital Management LP Invests $5.11 Million in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Names Frederick M. Lowery as Chief Executive Officer - Zenopa
Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Henry Schein Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途资讯
The Truth About Henry Schein Inc: Why Wall Street Is Watching (But TikTok Barely Cares…Yet) - AD HOC NEWS
Mizuho Adjusts Price Target on Henry Schein to $81 From $74, Maintains Neutral Rating - marketscreener.com
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Here's What to Expect From Henry Schein's Next Earnings Report - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Henry Schein (HSIC), Boston Scientific (BSX) - The Globe and Mail
Mixed Strategic Drivers Led Upslope Capital Management to Pick Henry Schein (HSIC) - Insider Monkey
Tetratherix executes global distribution & supply agreement with Henry Schein - marketscreener.com
Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein - TradingView — Track All Markets
Newly listed biotech Tetratherix secures global distribution deal with US giant Henry Schein - Business News Australia
Australia's Tetratherix hits four-week high on supply deal with Henry Schein - TradingView — Track All Markets
Henry Schein (NASDAQ:HSIC) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Henry Schein names new CEO - DrBicuspid.com
Henry Schein (HSIC) Valuation Check After Exclusive CitoCBC Distribution Agreement - Yahoo Finance
Henry Schein inks exclusive U.S. distribution deal for CLIA-waived CBC system - Medical Economics
Henry Schein enters distribution agreement for CytoChip's CLIA-waived hematology analyzer - marketscreener.com
Henry Schein Enters Distribution Agreement For CytoChip’S CLIA-Waived Hematology Analyzer - TradingView — Track All Markets
Henry Schein Agrees to Distribute CytoChip's CitoCBC system - marketscreener.com
Henry Schein (HSIC) Partners with CytoChip for Exclusive Distrib - GuruFocus
Henry Schein to distribute FDA-cleared blood test system nationwide - Investing.com
Henry Schein to distribute FDA-cleared blood test system nationwide By Investing.com - Investing.com South Africa
Henry Schein Enters Exclusive Distribution Agreement for CytoChip’s CLIA-Waived Hematology Analyzer - joplinglobe.com
3 Reasons to Sell HSIC and 1 Stock to Buy Instead - Yahoo Finance
Henry Schein names a new CEO - Digital Commerce 360
JPM26: Henry Schein focuses on high-margin, high-growth business as new CEO announced - Yahoo Finance
Henry Schein extends private placement facilities to 2028 - MSN
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - sharewise.com
Henry Schein Seeks M&A Opportunities - marketscreener.com
Henry Schein Taps Former Thermo Fisher Exec as New CEO - Modern Distribution Management
Will Henry Schein’s (HSIC) New External CEO and Governance Shift Reframe Its Leadership Narrative? - simplywall.st
Henry Schein Names Thermo Fisher Exec Fred Lowery as CEO - Medical Product Outsourcing
Frederick Lowery named new CEO of Henry Schein, effective March 2026 - Investing.com Nigeria
Henry Schein appoints Frederick Lowery as CEO - MSN
Leadership transition at Henry Schein: Frederick M. Lowery to take over as CEO - Dental Tribune US
Henry Schein names Frederick M. Lowery as new CEO - newsday.com
Henry Schein Appoints Frederick M Lowery as New CEO - Orthodontic Products
Henry Schein, Inc. Announces Management Changes - marketscreener.com
Henry Schein, Inc. Appoints Frederick M. Lowery as Chief Executive Officer, Effective March 2, 2026 - marketscreener.com
Henry Schein names Frederick Lowery as new CEO - libn.com
Henry Schein Inc (HSIC) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
1.19%
大文字化:
|
ボリューム (24 時間):